The Union Minister of AYUSH and Ports, Shipping & Waterways Shri Sarbananda Sonowal said that the northeastern region possess the greatest potential for the next phase of economic growth of the country. The diversity of flora in the region along with the rich heritage of traditional medicine will act as a catalyst for the development of AYUSH based industries in the region. The Union government is committed to elevate the economic proposition of the Northeast and provide the launch pad for India’s next economic growth.
The Minister was attending the review meeting of the North Eastern Institute of Ayurveda & Homeopathy held at Umiam in the Ri Bhoi district, Meghalaya. While speaking to the media person, the minister stressed about the need for best quality education for students of the region. The best education in Ayurveda nursing and pharmacy as well as professional short-term courses in Panchkarma Therapy so that students from Northeast and from other parts of the country can avail it. The minister stressed on training world class manpower who will be able to drive the economic growth.
The Union Minister said that the government remains committed to make northeast the growth engine of India. In this regard, he highlighted the rich & dynamic flora that nature has bestowed on us. There is a major opportunity for AYUSH based industries to look at northeast as the next destination for their new units. The world class professionals trained at NEIAH and other important training centers under Ministry of AYUSH will complement with the availability of the flora in the region to accelerate growth in the region.
The Union Minister stated that the Govt is committed to develop modern infra in NEIAH. He announced that the Govt will take steps to start PG courses at the institute and stipend for Homoeopathy interns will be increased at par with Ayurveda.
During the review meeting with the top officials of his ministry, the union minister took stock of the steps taken by the government to build capacity in the AYUSH led initiatives. He advised a few course corrections so that results from these initiatives can reach to the end users and people sooner than later.
Read More► Ministry of AYUSH Launches Online Portal to Ease The Process of Licensing Ayurveda Medicine
London- Researchers have identified an anti-viral gene that impacts the risk of both Alzheimer's disease and severe Covid-19.
A team from the University College London (UCL) estimated that one genetic variant of the OAS1 gene increases the risk of Alzheimer's disease by about 3-6 per cent in the population as a whole, while related variants on the same gene increase the likelihood of severe Covid-19 outcomes.
"While Alzheimer's is primarily characterised by harmful build-up of amyloid protein and tangles in the brain, there is also extensive inflammation in the brain that highlights the importance of the immune system in Alzheimer's. We have found that some of the same immune system changes can occur in both Alzheimer's disease and Covid-19," said lead author Dr Dervis Salih, from UCL's Queen Square Institute of Neurology and UK Dementia Research Institute.
"In patients with severe Covid-19 infection, there can also be inflammatory changes in the brain. Here we have identified a gene that can contribute to an exaggerated immune response to increase risks of both Alzheimer's and Covid-19," Salih added, in the paper published in the journal Brain.
To understand the gene's link to Alzheimer's, the team sequenced genetic data from 2,547 people, half of whom had the brain disorder.
They found that people with a particular variation, called rs1131454, of the OAS1 gene were more likely to have Alzheimer's disease, increasing carriers' baseline risk of Alzheimer's by an estimated 11-22 per cent.
The new variant identified is common, and it has a bigger impact on Alzheimer's risk than several known risk genes, the researchers said.
Further, the researchers investigated four variants on the OAS1 gene, all of which dampen its expression (activity).
They found that the variants increasing the risk of Alzheimer's are linked (inherited together) with OAS1 variants recently found to increase the baseline risk of needing intensive care for Covid-19 by as much as 20 per cent.
That is, the microglia cells where OAS1 gene was expressed more weakly had an exaggerated response to tissue damage, unleashing what they call a 'cytokine storm,' which leads to an autoimmune state where the body attacks itself, the team said.
OAS1 activity changes with age, so further research into the genetic network could help to understand why older people are more vulnerable to Alzheimer's, Covid-19, and other related diseases, they added.
Read More► Why Covid-19 is More Deadly for Some With Diabetes
Bhopal- A team of scientists at the Indian Institute of Science Education and Research (IISER) Bhopal have in a review identified the biomolecular relationships between Covid-19, ageing, and diabetes.
The review, published in the journal Molecular and Cellular Biochemistry, presented that existing drugs used to treat diabetes, obesity and ageing can potentially be used to treat Covid-19. Similar naturally existing biomolecules were also explored in combination for the Covid treatment.
"There are classes of compounds such as polyphenols found in plant-based food, curcumin (found in turmeric), and resveratrol (found in grapes), have been shown to not only slow down the ageing process, but also possess anti-viral properties," said Dr. Amjad Husain, Principal Scientist, and CEO of Innovation and Incubation Center for Entrepreneurship (IICE), IISER Bhopal, in a statement.
Some other polyphenols that the researchers have identified as being useful for both Covid-19 treatment and comorbidity conditions such as diabetes and ageing may include catechins (present in green tea, cocoa and berries), procyanidins (found in apples, cinnamon and grape skin), and theaflavin (found in black tea).
The researchers also present evidence of some existing potential anti-ageing drugs such as Rapamycin that can be explored for the Covid-19 treatment because of the common biochemical pathways associated with these diseases. Another such example is a drug Metformin , which is usually used to control blood sugar.
The review showed that at the molecular level, there are intersecting pathways that are common to diabetes, ageing, and Covid-19. All three conditions are associated with oxidative stress and lowering of the immune response and complications arising from them lead to the onset of numerous other diseases such as cardiovascular disorders, eye diseases, neuropathy (nerve diseases), and nephropathy (kidney problems).
The researchers believe that an ideal therapeutic candidate for Covid-19 should be able to target the pathways that are common to diabetes, ageing and the SARS-CoV-2 infection.
Further, computational studies showed that lipids present in cell membranes play an important role in coronavirus infectivity.
Natural compounds such as polyphenols may affect the binding of the virus to host receptors and the molecular interactions required for virus replication and release, thereby stopping the infection in its early stages, the team explained.
Read More► Risk of Stroke Increases With Insulin Resistance: Study
आयुष मंत्रालय ने आवेदन प्रणाली को ऑनलाइन बनाकर आयुर्वेद, सिद्ध और यूनानी (एएसयू) दवाओं के निर्माण के लिए लाइसेंस देने की प्रक्रिया को तीव्र, पेपरलेस और अधिक पारदर्शी बना दिया है।
निर्माता अब लाइसेंसिंग प्राधिकरण के कार्यालय में खुद की उपस्थिति की परेशानी से बच सकते हैं और अब www.e-aushadhi.gov.in पर लाइसेंस के लिए ऑनलाइन आवेदन कर सकते हैं। आयुष मंत्रालय ने 1 अक्टूबर, 2021 से औषधि (चौथा संशोधन) नियमावली, 2021 के कार्यान्वयन को अधिसूचित करते हुए एक राजपत्र आदेश जारी किया।
एएसयू दवाओं का लाइसेंस हमेशा के लिए बना दिया गया है, यानी एकमुश्त पंजीकरण शुल्क के साथ उत्पाद का लाइसेंस हमेशा के लिए विधि मान्य होगा, बशर्ते, हर साल ऑनलाइन स्व-अनुपालन घोषणा जमा करने के अधीन अथवा निलंबित या रद्द न हुआ हो। जबकि, अधिसूचना से पहले इसकी वैधता अवधि 5 वर्ष थी।
आवेदकों को केवल अपने लाइसेंस को लागू रखने के लिए हर पांच साल में अपने गुड मैन्युफैक्चरिंग प्रैक्टिस सर्टिफिकेशन को मान्य करवाना होगा। 1000 रुपये के प्रतिधारण शुल्क को ऑनलाइन जमा करने के साथ जीएमपी प्रमाणपत्र को भी बरकरार रखा जा सकता है। एएसयू दवाओं की निर्माण इकाई का हर 5 साल मोटे तौर पर निरीक्षण किया जाएगा। चूंकि, लाइसेंस की वैधता बढ़ा दी गई है, इसलिए किसी भी संख्या में जेनेरिक एएसयू दवाओं के लिए लाइसेंस शुल्क को 1,000 रुपये से बढ़ाकर 2,000 रुपये और अधिकतम 10 मालिकाना एएसयू दवाओं के लिए 3,000 रुपये कर दिया गया है।
मंत्रालय ने लाइसेंस देने में लगने वाले अधिकतम समय को भी तीन महीने से घटाकर दो महीने कर दिया है।
राजपत्र अधिसूचना की तारीख से छह महीने के लिए, पूरी तरह से ऑनलाइन होने से पहले, ऑनलाइन और ऑफलाइन दोनों आवेदन प्रक्रिया अस्तित्व में रहेगी।
आवेदन प्रणाली को ऑनलाइन करने से पूरी प्रक्रिया में एकरूपता आएगी। आयुष मंत्रालय लाइसेंसिंग प्रक्रिया में एक सूत्रधार के रूप में कार्य करेगा।
इन सुधारों/उपायों से एएसयू दवाओं की गुणवत्ता, सुरक्षा और प्रभावकारिता सुनिश्चित करते हुए व्यवसाय करने में आसानी लाने के इरादे से एएसयू औषधि निर्माताओं पर नियामक अनुपालन का बोझ कम होगा।
यह भी पढ़े ► आयुर्वेद के क्षेत्र में अकादमिक अनुसंधान को लेकर भारत और क्रोएशिया के बीच समझौता
New York - Women who contract Covid-19 during pregnancy are at significantly higher risk of developing pre-eclampsia, the leading cause of maternal and infant death worldwide, according to a new study.
Pre-eclampsia is a sudden increase in blood pressure after the 20th week of pregnancy.
The study, published in the American Journal of Obstetrics and Gynecology, showed that women with SARS-CoV-2 infection during pregnancy had 62 per cent higher odds of developing preeclampsia than those without the infection during pregnancy.
"This association was remarkably consistent across all predefined subgroups. Moreover, SARS-CoV-2 infection during pregnancy was associated with a significant increase in the odds of pre-eclampsia with severe features, eclampsia and HELLP syndrome," said Roberto Romero, Professor of Molecular Obstetrics and Genetics at the Wayne State University School of Medicine.
HELLP syndrome is a form of severe pre-eclampsia that includes hemolysis (the rupturing of red blood cells), elevated liver enzymes and a low platelet count.
The team published their findings after reviewing 28 previous studies that included 790,954 pregnant women, including 15,524 diagnosed with Covid-19 infection.
"Both asymptomatic and symptomatic infection significantly increased the risk of pre-eclampsia," Romero said.
"Nevertheless, the odds of developing pre-eclampsia were higher among patients with symptomatic illness than among those with asymptomatic illness."
Pre-eclampsia warning signs, in addition to elevated blood pressure, can include headaches, swelling in the face and hands, blurred vision, chest pain and shortness of breath.
The condition is responsible for 76,000 maternal deaths and more than 500,000 infant deaths every year, according to estimates from the Pre-eclampsia Foundation.
The babies of pre-eclamptic mothers are affected by the condition and may develop intrauterine growth restriction or die in utero.
The researchers said health care professionals should be aware of the association and closely monitor pregnant women who are infected for early detection of pre-eclampsia.
A separate study, published in the American Journal of Obstetrics and Gynecology-Maternal-Fetal Medicine, showed that women who receive the mRNA Covid-19 vaccine during pregnancy pass high levels of antibodies to their babies.
The study of 36 newborns whose mothers received either the Pfizer-BioNTech or Moderna Covid-19 vaccine during pregnancy showed that 100 per cent of the infants had protective antibodies at birth.
Read More► Viral fever rages in Bihar among kids
The central government has increased the financial support from Rs nine crore to Rs 70 crore to ensure more Ayush colleges are opened across the country, Union Minister for Ayush and Ports, Shipping & Waterways, Sarbananda Sonowal, said on Saturday. The Minister was addressing a conference on ‘Diverse and Fulfilling Career Paths in Ayush Systems: Education, Entrepreneurship & Employment Focus on North eastern States’ in Guwahati.
The Union minister said that there are only a few Ayush colleges in the North-East and the Indian traditional medicine systems can only be popularised by making available more qualified practitioners.
“For this purpose, more Ayush teaching colleges may be required to come up in the North East States. Earlier under Centrally Sponsored Scheme of National Ayush Mission provided financial support of Rs.9 crores to state governments to open new Ayush colleges. Now, the Government of India has enhanced this amount to Rs.70 crore. States may identify the land and manpower for this purpose and avail this opportunity as per the guidelines of the NAM,” Sonowal said.
Sonowal added that the Ministry of Ayush has also accorded in-principle approval for upgrading the Government Ayurvedic College, Jalukbari, Assam as the Centre of Excellence with the support of up to Rs 10 crore. He said that his Ministry provides Rs. 5 crore to upgrade the under-graduate teaching colleges and Rs. 6 crores to improve the infrastructure of post graduate institutions.
The minister also announced the starting of a Panchkarma Technician course affiliated to Health Sector Skill Council - National Skill Development Corporation at Central Ayurveda Research Institute (CARI), Guwahati with 10 seats for 10+2 students to produce skilled manpower for Panchkarma therapy in NE region and enhance the employment opportunities in that part of the country.
“Career opportunities in the Ayush sector for professionals of all disciplines have increased dramatically during recent years. Moreover, consequent to these efforts, faith in the Ayush cesystems has been restored among communities worldwide,” Sonowal said. He added that Ayush has a great potential to cater to a large number of healthcare needs of people and contribute to the growth and development of this country.
Minister of Health & Family Welfare and Science & Technology and Information & Broadcasting in the Government of Assam, Keshab Mahanta, was the guest of honour at the conference.
The Ministry of Ayush had earlier this month successfully held a landmark conference of Ayush ministers of all north-eastern states and deliberated upon the developing the infrastructure for popularizing Ayush stream in the region. Today’s conference was the next step with experts discussing the education and career opportunities in Ayush.
The presentation on ‘Career Opportunities, Education in Ayurveda’ was made by Vaidya Jayant Yeshwant Deopujari, Chairperson of National Commission for Indian System of Medicine (NCISM). It was followed by session on Career opportunity and Exploration of Potential of Ayush in North Eastern States. In this session, Prof. Sanjeev Sharma, Director, National Institute of Ayurveda, Jaipur gave a lecture on ‘Education & Career Opportunities in Ayurveda in North Eastern States’ and Dr. N. Srikanth, Director General, CCRAS, New Delhi spoke on ‘Research & Development in North Eastern States India’.
There was a special address by Mrs. Indrani Mahto, Manager, Startup India, Department for Promotion of Industry and Internal Trade, on ‘Entrepreneurship in Ayush sector ‘Start Up’.
Lecture on ‘Career Opportunities in Homeopathy; Industrial Perspective in North Eastern States’ was given by Dr. Subhas Singh, Director, NIH, Kolkata; lecture on ‘Career Opportunities Education in Homeopathy in North Eastern States was given by Dr. Tarkeshwar Jain, Secretary, NCH, New Delhi and ‘Research & Development and Public Health in North East India’ was given by Dr. Subhash Chaudhary, NIH, Kolkata.
Similarly, a lecture on ‘Research Education and Career Opportunity in Unani’ was given by Prof. Asim Ali Khan, Director General, CCRUM, New Delhi on ‘Research Education and Career Opportunity in Siddha’ was given by Prof. Dr. K. Kanakavalli, Director General, CCRS, Chennai on ‘Research Education and Career Opportunity in Sowa-Rigpa’ by Dr. Padma Gurmeet, Director, NRIS, Leh and ‘Research Education and Career Opportunity in Yoga & Naturopathy’ was given by Dr. Raghvendra Rao, Director, Central Council for Research in Yoga and Naturopathy, New Delhi. This session is followed by presentation of representatives of Ayush Industries on ‘Career opportunity & Entrepreneurship: Industry perspective’ which followed Interactive Session with Ayush Students and Scholars from different areas of North eastern states.
About 250 participants, including the officials from the Ministry of Ayush, Ayush Institutes and Research Councils and Ayush Colleges in NE States attended the conference.
Read More► IISER Bhopal Genome Sequencing Immune Boosting Herb Giloy